



Advances in Drug Treatment for Leishmaniasis

Guest Editor:

Dr. Juliana Carnielli

York Biomedical Research
Institute, Department of Biology,
University of York, York YO10 5DD,
UK

Deadline for manuscript
submissions:

closed (15 June 2023)

Message from the Guest Editor

Globally distributed and closely related to poverty, the leishmaniases are neglected tropical diseases, with more than 1 billion people at risk of infection. Given the difficulties associated with vector control and the absence of an effective vaccine, leishmaniasis control relies primarily on chemotherapy. Nevertheless, current therapies have severe shortcomings, highlighting an urgent need for innovative safe and efficacious treatments, understanding the mechanism of resistance to preserve the current available drugs, and the development of innovative approaches for disease control.

This Special Issue aims to gather relevant manuscripts, from basic to translational studies, to cover different aspects of the recent advances in drug treatment for leishmaniasis: current chemotherapy and recent advances in drug treatment for leishmaniasis; drug combination; immunotherapy; drug-delivery systems for the treatment of leishmaniasis; target identification and validation in *Leishmania*; drug development for leishmaniasis; drug resistance to leishmaniasis; mechanisms of drug action and drug resistance; prognostic markers for leishmaniasis treatment and diagnosis; etc.

